Sherwin Abdoli1, Steven Katz2, Christian Ochoa2. 1. Department of Surgery, Huntington Memorial Hospital, Pasadena, CA. Electronic address: Sherwin.Abdoli@gmail.com. 2. Department of Surgery, Huntington Memorial Hospital, Pasadena, CA; Division of Vascular Surgery and Endovascular Therapy, University of Southern California, Los Angeles, CA.
Abstract
BACKGROUND: Treatment of peripheral arterial disease (PAD) has become increasingly dominated by endovascular interventions. The short-term outcomes of endovascular therapy have been well studied, but late outcomes remain largely unpublished; in this series, we report the late outcomes of primary nitinol stenting. METHODS: All patients undergoing primary nitinol stenting of the superficial femoral artery (SFA) and/or popliteal artery (PA) during a 10-year period by a single surgeon (S.K.) were reviewed. No attempts were made on patients with orificial or total occlusion of the SFA, PA, and proximal tibial arteries. Differences in primary patency, primary-assisted patency, secondary patency, and freedom from bypass were evaluated at 1, 5, and 9 years. RESULTS: A total of 294 limbs in 240 patients were treated. One hundred and thirty additional endovascular procedures were observed during the study period averaging to 0.16 endovascular interventions per limb per year. Primary patency in TASC A/B limbs at 1, 5, and 9 years was 79%, 35%, and 19%, respectively, and in TASC C/D limbs was 62%, 11%, and 3%, respectively. Secondary patency in TASC A/B limbs at 1, 5, and 9 years was 96%, 81%, and 65%, respectively, and in TASC C/D limbs was 92%, 64%, and 41%, respectively. Freedom from bypass in TASC A/B limbs at 1, 5, and 9 years was 98%, 89%, and 85%, respectively, and in TASC C/D limbs was 95%, 78%, and 69%, respectively. Five below-the-knee amputations were observed during the study period. CONCLUSIONS: An endovascular-first approach can be applied to the vast majority of femoropopliteal lesions. While the late outcomes of TASC C/D lesions are inferior to those of TASC A/B lesions, an endovascular-first approach still provides durable outcomes.
BACKGROUND: Treatment of peripheral arterial disease (PAD) has become increasingly dominated by endovascular interventions. The short-term outcomes of endovascular therapy have been well studied, but late outcomes remain largely unpublished; in this series, we report the late outcomes of primary nitinol stenting. METHODS: All patients undergoing primary nitinol stenting of the superficial femoral artery (SFA) and/or popliteal artery (PA) during a 10-year period by a single surgeon (S.K.) were reviewed. No attempts were made on patients with orificial or total occlusion of the SFA, PA, and proximal tibial arteries. Differences in primary patency, primary-assisted patency, secondary patency, and freedom from bypass were evaluated at 1, 5, and 9 years. RESULTS: A total of 294 limbs in 240 patients were treated. One hundred and thirty additional endovascular procedures were observed during the study period averaging to 0.16 endovascular interventions per limb per year. Primary patency in TASC A/B limbs at 1, 5, and 9 years was 79%, 35%, and 19%, respectively, and in TASC C/D limbs was 62%, 11%, and 3%, respectively. Secondary patency in TASC A/B limbs at 1, 5, and 9 years was 96%, 81%, and 65%, respectively, and in TASC C/D limbs was 92%, 64%, and 41%, respectively. Freedom from bypass in TASC A/B limbs at 1, 5, and 9 years was 98%, 89%, and 85%, respectively, and in TASC C/D limbs was 95%, 78%, and 69%, respectively. Five below-the-knee amputations were observed during the study period. CONCLUSIONS: An endovascular-first approach can be applied to the vast majority of femoropopliteal lesions. While the late outcomes of TASC C/D lesions are inferior to those of TASC A/B lesions, an endovascular-first approach still provides durable outcomes.
Authors: John R Laird; Thomas Zeller; Christian Loewe; Jack Chamberlin; Richard Begg; Peter A Schneider; Aravinda Nanjundappa; Frank Bunch; Scott Schultz; Stuart Harlin; Alexandra Lansky; Michael R Jaff Journal: J Endovasc Ther Date: 2017-12-29 Impact factor: 3.487
Authors: Hans Krankenberg; Michael Schlüter; Hermann J Steinkamp; Karlheinz Bürgelin; Dierk Scheinert; Karl-Ludwig Schulte; Erich Minar; Patrick Peeters; Marc Bosiers; Gunnar Tepe; Bernhard Reimers; Felix Mahler; Thilo Tübler; Thomas Zeller Journal: Circulation Date: 2007-06-25 Impact factor: 29.690
Authors: F Gerald R Fowkes; Diana Rudan; Igor Rudan; Victor Aboyans; Julie O Denenberg; Mary M McDermott; Paul E Norman; Uchechukwe K A Sampson; Linda J Williams; George A Mensah; Michael H Criqui Journal: Lancet Date: 2013-08-01 Impact factor: 79.321
Authors: Charlie C-T Hsu; Gigi Nc Kwan; Dalveer Singh; John A Rophael; Chris Anthony; Mieke L van Driel Journal: Cochrane Database Syst Rev Date: 2018-12-08
Authors: Monika Colombo; Yong He; Anna Corti; Diego Gallo; Stefano Casarin; Jared M Rozowsky; Francesco Migliavacca; Scott Berceli; Claudio Chiastra Journal: Sci Rep Date: 2021-01-15 Impact factor: 4.379